EPO and anemia: More significantly, a head-to-head comparison with darbepoetin alfa, which has been extensively used in clinic, showed that the hyFc-fusion strategy more effectively improved recovery from cisplatin-induced anemia as well as the in vivo bioactivity of EPO in normal rats than did the hyperglycosylation approach, especially after subcutaneous (SC) administration.